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Background: The therapy with beta-blockers is fundamental for the treatment of heart failure. However, even with the data documenting the 
incontestable benefits of beta-blockers, the level of medical prescriptions are still far from being optimized.
Methods: In a randomized clinical 3-month study, we selected 92 patients with heart failure and ejection fraction of the left ventricle (LVEF) 
<45%.During hospitalization, 46 were placed randomly to receive therapy with beta-blockers by the fast method ( fast-carvedilol group), initiating 
treatment with low dosages and doubling dosage every two days. In the comparative sample (usual-treatment group), the other 46 received the 
usual therapy currently applied where the increase of the dosage was 10-15 days.
Results: In the total group studied, 64,1% were male, with an avarage age of 62.25 years. The LVEF avarage was 27.02, the end diastolic diamenter 
(EDD) avarage was 66.15, and the end sistolic diameter (ESD) avarage was 57.04. The usual treatment group did not present a significant alteration 
of the (ESD) during the 3-month treatment period (p=0.430). On the other hand, the fast-carvedilol group presented a significant decrease 
(p<0.001) of the (ESD). In relation to the (EDD), the usual treatment group did not show significant change during the three months of the study 
(p=0.082), but the fast-carvedilol group showed a significant decrease (p=0.007). In relation to (LVEF), the usual treatment group did not show 
any change (p=0.151), but the fast-carvedilol group showed a significant increase (p<0.001). The fast-carvedilol group, presented significant lower 
mortality levels than the other group during the period evaluated (p=0.05).
Conclusions: The therapy with beta-blocker, utilized in a more rapid method during the hospitilazition of the patient, resulted in a safer and more 
superior treatment for obtaining survival and ventricular remodeling in comparation to the usual-treatment group.
